Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck R&D: A Jam-Packed Pipeline But Much Of It Wait-And-See

This article was originally published in The Pink Sheet Daily

Executive Summary

Following the acquisition of Schering-Plough, Merck has one of the most robust pipelines in the industry, but after an R&D day May 11, much of the most interesting data is still yet to be seen.

You may also be interested in...



FDA Panel Will Have To Resolve Bleeding Risk With Merck’s Vorapaxar

Novel antiplatelet product has suffered from excess bleeding rates in clinical trials and is searching for an appropriate patient population, after initial hopes of being a blockbuster.

Merck Plans To Shed 13% Of Work Force By 2015

The pharma responds to a tough market environment by stepping up its previously-announced cost savings program to total $4 billion to $4.6 billion a year by 2015.

Merck Plans To Shed 13% Of Work Force By 2015

The pharma responds to a tough market environment by stepping up its previously-announced cost savings program to total $4 billion to $4.6 billion a year by 2015.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS070613

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel